一位67岁男性患者表现为广泛期小细胞肺癌，原发病灶位于右上肺，并伴有多发转移至胸膜和腹腔以及肺门淋巴结肿大。在局部放疗后，采用联合治疗方案针对患者的多系统转移。该方案涉及采用程序性死亡配体1（PD-L1）增强的外源性自然杀伤（NK）细胞进行细胞治疗，同时进行抗血管生成治疗。异基因脐血NK细胞以两天为周期输注至患者体内。首日治疗后，接受1200mg阿特珠单抗。随后，患者每日口服10mg安乐脉治疗14天，随后休药7天，一个周期持续21天。在给予右肺原发病灶和转移性肺门淋巴结局部放疗后，达到了局部病灶的完全缓解，有效避免了上腔静脉综合征的风险。经过六个周期的联合治疗后，大部分转移病灶已消失，其余转移病灶的大小显著减小。当前治疗效果为部分缓解。细胞治疗和抗血管生成靶向治疗的联合疗法展示了令人满意的短期效果，大部分转移病灶消失，并且其余转移病灶明显收缩。© 2023 作者。《胸部肿瘤》由中国肺癌学会和John Wiley & Sons Australia, Ltd出版。

A 67-year-old male patient presented with extensive-stage small cell lung cancer with the primary lesion located in the right upper lung, accompanied by multiple metastases to the pleura and abdominal cavity with enlarged mediastinal lymph nodes. A combination therapy approach was used to target the patient's multiple systemic metastases after localized radiotherapy. The approach involved adoptive transfer of programmed death ligand 1 (PD-L1) enhanced exogenous natural killer (NK) cells, along with antiangiogenic treatment. Allogeneic cord blood NK cells were infused back into the patient over two consecutive days. On the first day, the treatment was followed by a dose of 1200 mg of atezolizumab. Subsequently, the patient received a daily dose of 10 mg of anlotinib administered orally for 14 days. This was followed by a 7-day break, and each cycle lasted 21 days. After delivering localized radiation to the primary lesion in the right lung and metastatic mediastinal lymph nodes, complete remission was achieved in the local lesion, effectively avoiding the risk of superior vena cava syndrome. Following six cycles of combined therapy, most of the metastatic lesions had disappeared, and the remaining metastatic lesions had significantly reduced in size. The recent therapeutic effect resulted in partial remission. The combination therapy of immune checkpoint inhibitor PD-L1-enhanced exogenous adoptive transfer NK cells, along with antiangiogenic targeted treatment, demonstrated a satisfactory short-term effect, with disappearance of most of the metastases and noticeable shrinkage in the remaining metastatic lesions.© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.